Table 1.
Current clinical trials for conventional chondrosarcoma (March 2020).
| Clinical Trial | Agent | Mechanism of Action | Study Design | Study Population | Status |
|---|---|---|---|---|---|
| IDH Inhibitors | |||||
| NCT03684811 | FT-2102 or FT-2102 plus azacytidine | Oral IDH-1 inhibitor in combination with hypomethylating agent | Phase 1/2 | Advanced solid tumors and gliomas including chondrosarcoma with IDH1 mutation | Recruiting |
| NCT04278781 | AG-120 | Oral IDH-1 inhibitor | Phase 2 | IDH1 mutant chondrosarcoma | Recruiting |
| Angiogenesis Inhibitors | |||||
| NCT02389244 | Regorafenib | Multi-kinase inhibitor, targeting antiandrogenic, stromal and oncogenic receptor tyrosine kinase | Phase 2 | Metastatic bone sarcoma, chondrosarcoma | Recruiting |
| Cyclin-dependent Kinase (CDK) Inhibitors | |||||
| NCT04040205 | Abemaciclib | CDK 4/6 inhibitor | Phase 2 | Advanced bone sarcoma including chondrosarcoma | Recruiting |
| P13k-Akt-mTOR Pathway | |||||
| NCT02821507 | Combination sirolimus and cyclophosphamide | mTOR inhibition with cyclophosphamide | Phase2 | Metastatic or unresectable myxoid liposarcoma, chondrosarcoma | Recruiting |
| Osteoclast Inhibitors | |||||
| NCT03173976 | Zoledronic acid | Bisphosphonate therapy influencing osteoclast activity | Phase 1b | Resectable chondrosarcoma | Recruiting |
| Epigenetic therapy | |||||
| NCT02959164 | Combination gemicitabine and decitabine | Demethylation and inhibition of DNA synthesis | Phase 1B | Advanced malignancies, bone sarcomas | Active, not recruiting |
| NCT04340843 | Combination belinostat and guadecitabine | HDAC inhibitor together with demethylation | Phase 2 | Conventional Chondrosarcoma | Not recruiting |
| Immune Checkpoint Inhibitors | |||||
| NCT03190174 | Combination nivolumab and nab-rapamycin (ABI-009) | Anti-PD1 | Phase 1/2 | Advanced malignancies, including sarcomas with deficient mismatch repair | Recruiting |
| NCT03474640 | Toripalimab | Anti-PD1 | Phase 1 | Advanced malignancies including chondrosarcoma | Recruiting |
| NCT02982486 | Combination nivolumab and ipilimumab | Anti-PD1 | Phase 2 | Unresectable sarcomas, including chondrosarcoma | Not yet recruiting |
| NCT02888665 | Combination pembrolizumab and doxorubicin | Anti-PD1 | Phase 1/2 | Advanced sarcomas | Active, not recruiting |
| NCT03277924 | Nivolumab plus Sunitinib | Anti PD-1 plus tyrosine kinase inhibitor | Phase 1/2 | Advanced bone sarcomas | Recruiting |